Business
Innocan Pharma Announces First Patent Grant in the United States
This is the first fully granted patent of Innocan in the United States The Patent covers Innocan...
About this update from Innocan Pharma Corporation
[{"type":"text","content":"Innocan Pharma Announces First Patent Grant in the United StatesThis is the first fully granted patent of Innocan in the United StatesThe Patent covers Innocan's proprietary cannabis-based pain relief topical This serves as an indication of Innocan's growing intellectual property portfolioHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 12, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the \"Company\" or \"Innocan\") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property (IP) portfolio, is pleased to announce that the United States Patent and Trademark Office (\"USPTO\") has issued a Notice of Allowance for Innocan's patent application number 16/968,627 with claims related to the Company's combined cannabis and magnesium topical pain-relief technology (the \"Patent\"). The Patent discloses and claims breakthrough magnesium and cannabis-based technology that is administered topically. The technology is designed to systemically relieve pain and/or itching, and is administered via spray, roll-on or lotion.The Company intends to file further patent applications with the USPTO, as well with other patent offices worldwide, in order to further establish its novel cannabis-based IP portfolio. Innocan Pharma's CEO, Iris Bincovich, stated, \"We are glad to see a robust and vivid indication of our pain relief technology, adding to Innocan's intellectual property portfolio. Receiving the patent approval from the USPTO will assist us in our commercialization efforts.\"About InnocanInnocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergist...